Strata Wealth Advisors LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 10.2% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,414 shares of the company’s stock after acquiring an additional 131 shares during the quarter. Strata Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $219,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors also recently bought and sold shares of the stock. GW&K Investment Management LLC bought a new position in Johnson & Johnson during the 4th quarter valued at approximately $35,000. Dark Forest Capital Management LP raised its position in Johnson & Johnson by 1,044.4% during the 4th quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock valued at $36,000 after purchasing an additional 188 shares during the last quarter. Ruedi Wealth Management Inc. bought a new position in Johnson & Johnson during the 4th quarter valued at approximately $42,000. Kepos Capital LP bought a new position in Johnson & Johnson during the 4th quarter valued at approximately $45,000. Finally, 25 LLC bought a new position in shares of Johnson & Johnson in the 1st quarter worth approximately $55,000. 67.57% of the stock is currently owned by hedge funds and other institutional investors.
Insider Transactions at Johnson & Johnson
In other news, insider William Hait sold 14,698 shares of the firm’s stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the transaction, the insider now directly owns 87,747 shares in the company, valued at approximately $15,092,484. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, insider William Hait sold 14,698 shares of the firm’s stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the transaction, the insider now directly owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Peter Fasolo sold 20,000 shares of the firm’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the transaction, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The disclosure for this sale can be found here. Insiders have sold a total of 47,163 shares of company stock worth $7,928,856 in the last ninety days. Insiders own 0.20% of the company’s stock.
Analyst Ratings Changes
Read Our Latest Stock Report on Johnson & Johnson
Johnson & Johnson Stock Performance
Shares of JNJ opened at $164.89 on Friday. The business’s fifty day simple moving average is $166.64 and its two-hundred day simple moving average is $161.48. The company has a current ratio of 1.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 12 month low of $150.11 and a 12 month high of $181.04. The company has a market cap of $428.54 billion, a price-to-earnings ratio of 33.38, a P/E/G ratio of 2.76 and a beta of 0.54.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its earnings results on Thursday, July 20th. The company reported $2.80 EPS for the quarter, beating the consensus estimate of $2.62 by $0.18. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The business had revenue of $25.53 billion for the quarter, compared to the consensus estimate of $24.63 billion. During the same period last year, the business posted $2.59 EPS. The company’s revenue was up 6.3% compared to the same quarter last year. Research analysts anticipate that Johnson & Johnson will post 10.75 earnings per share for the current fiscal year.
Johnson & Johnson Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Monday, August 28th will be paid a $1.19 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.89%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 96.36%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- When to Sell a Stock for Profit or Loss
- Can These 2 Industrial Titans Extend Double-Digit YTD Growth?
- What is a Stock Market Index and How Do You Use Them?
- How to Profit from These 3 Membership Club Stocks’ Strengths
- Investing in Travel Stocks Benefits
- 5 Best High-Yield Dividend Stocks for Any Economic Climate
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
